fig3

Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer

Figure 3. Metabolomics and metabolic imaging applications in PCa. Schematic overview of metabolomics and metabolic imaging applications in biomarker discovery and in therapy response assessment. ADT: androgen deprivation therapy; ARSI: androgen receptor signaling inhibitors; MSI: mass spectrometry imaging; MRI: magnetic resonance imaging; MRSI: magnetic resonance spectroscopy imaging; PET: positron emission tomography

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/